ABVC BioPharma, Inc. (ABVC)
0.9601
-0.04
(-3.99%)
USD |
NASDAQ |
Sep 04, 16:00
0.9471
-0.01
(-1.35%)
Pre-Market: 20:00
ABVC BioPharma Research and Development Expense (Quarterly) : 0.0227M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0227M |
| March 31, 2026 | 0.0331M |
| December 31, 2025 | 0.0291M |
| September 30, 2025 | 0.0299M |
| June 30, 2025 | 0.0333M |
| March 31, 2025 | 0.0289M |
| December 31, 2024 | 0.032M |
| September 30, 2024 | 0.0378M |
| June 30, 2024 | 0.0404M |
| March 31, 2024 | 0.0691M |
| December 31, 2023 | 0.0722M |
| September 30, 2023 | 0.1413M |
| June 30, 2023 | 0.5144M |
| March 31, 2023 | 0.335M |
| December 31, 2022 | 1.496M |
| September 30, 2022 | 0.3055M |
| June 30, 2022 | 0.5328M |
| March 31, 2022 | 0.3594M |
| September 30, 2021 | 0.2634M |
| June 30, 2021 | 0.3589M |
| March 31, 2021 | 0.1213M |
| December 31, 2020 | 0.1833M |
| September 30, 2020 | 0.1345M |
| June 30, 2020 | 0.1391M |
| March 31, 2020 | 0.0928M |
| Date | Value |
|---|---|
| December 31, 2019 | 0.2696M |
| September 30, 2019 | 0.2692M |
| June 30, 2019 | 0.0878M |
| March 31, 2019 | 0.422M |
| December 31, 2018 | 0.6294M |
| September 30, 2018 | 0.0545M |
| June 30, 2018 | 0.0567M |
| March 31, 2018 | 0.2481M |
| December 31, 2017 | 0.0457M |
| September 30, 2017 | 3.126M |
| June 30, 2017 | 0.0175M |
| December 31, 2016 | 0.0252M |
| September 30, 2016 | 10.00M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 6.50M |
| December 31, 2015 | 3.50M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 0.00 |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 7.341M |
| Perspective Therapeutics, Inc. | 20.40M |
| MiMedx Group, Inc. | 2.777M |
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 8.178M |